Approximately 30–40% of breast cancers are estrogen receptor (ER) negative and the triple negative breast cancer (TNBC i.e. negative for ERα, PR and Her2 amplification) are the most clinically aggressive breast tumors [1], [2]. Here, ESR1 is linked to breast neoplasm.